Detail akcie Arcus Biosciens Rg online

Business Summary: Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Arcus Biosciences Inc revenues decreased 81% to $28M. Net loss increased from $4M to $112M. Revenues reflect License And Development Services Revenue decrease of 85% to $20M, Other collaboration revenue decrease of 20% to $8M. Higher net loss reflects Research and development - Balancing val increase of 15% to $114M (expense), Interest and other income, net decrease of 15% to $11M (income).